Quantcast

Latest Sirolimus Stories

2014-07-09 08:28:18

-- Newly Issued US Patent Covers Medical Device Coating Process and Compositions -- DURHAM, N.C., July 9, 2014 /PRNewswire/ -- Micell Technologies, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued a patent related to Micell's technology for enhancing the performance of medical devices with precise drug-delivery coatings. These technologies currently are used in producing the company's drug-eluting stent system, MiStent SES(®). The...

2014-06-03 16:25:04

HORSHOLM, Denmark, June 3, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced the hiring of senior level management in preparation for potential U.S. commercialization of Envarsus(®) XR (tacrolimus extended-release tablets) an investigational new drug under FDA review for the prevention of organ rejection in adult kidney transplant patients. Key points: -- Envarsus( )XR is an extended release formulation of tacrolimus being designed for once-daily...

2014-05-23 08:23:56

-- Sustained Safety Profile -- DURHAM, N.C., May 23, 2014 /PRNewswire/ -- Micell Technologies, Inc. today announced that long-term clinical outcomes from its DESSOLVE I and II clinical trials were presented at the EuroPCR conference in Paris, France this week. Presentations by principal investigator William Wijns, M.D., Ph.D. of the Cardiovascular Center in Aalst, Belgium, highlighted results of long-term clinical follow-up of the MiStent Sirolimus Eluting Absorbable Polymer Coronary...

2014-05-23 04:20:45

COMBO(TM) Dual Therapy Stent shown to actively promote rapid endothelialization and deliver long-term, true vessel healing HONG KONG, May 23, 2014 /PRNewswire/ -- OrbusNeich today announced long-term results from its REMEDEE Trial. In addition to showing that the COMBO(TM) Dual Therapy Stent shows no late target lesion revascularization, the results demonstrate that the stent proactively promotes functional vessel healing. Key findings include: -...

2014-05-20 08:34:22

AADi Initiates NIH Funded Clinical Trial for Patients with Bladder Cancer PACIFIC PALISADES, Calif., May 20, 2014 /PRNewswire/ -- AADi, LLC, a clinical stage biopharmaceutical company focused on treating diseases uniquely suited for nanotechnology approaches, today announced the inlicensing of ABI-009 from Celgene Corporation (NASDAQ:CELG). ABI-009 is the nanoparticle albumin-bound (nab®) version of the mTOR inhibitor sirolimus or rapamycin and leverages the same technology of the...

2014-05-15 16:28:10

-- Oral Presentations to Include New Long-Term Results from First-in-Human Study -- DURHAM, N.C., May 15, 2014 /PRNewswire/ -- Micell Technologies, Inc. today announced the updated three- and two-year clinical outcomes from its DESSOLVE I and II clinical trials, respectively, will be presented at the EuroPCR conference to be held in Paris, France from May 20 - 23. Two oral presentations will be made by William Wijns, M.D., Ph.D., Cardiovascular Center, Aalst, Belgium: -- DESSOLVE II...

2014-04-28 23:04:36

Findings Show Several FDA-Approved Drugs May also be Effective in Patients Diagnosed with Dilated Cardiomyopathy New York, NY (PRWEB) April 28, 2014 Scientists at Icahn School of Medicine at Mount Sinai, along with collaborators at institutions in India, Italy, and Japan, have identified the first gene linked to childhood-onset familial dilated cardiomyopathy (DCM), one of the most common heart muscle diseases in children. It is a progressive and potentially fatal heart condition...

2014-04-03 12:58:10

New research suggests that drugs commonly used to prevent organ rejection after transplantation may also be helpful for combating HIV. The findings, which are published in the American Journal of Transplantation, suggest a new strategy in the fight against HIV and AIDS. Despite the effectiveness of antiviral therapies at suppressing HIV, the virus still persists indefinitely at low levels in infected patients who are diligent about taking their medications. "Current therapies fail to cure...

2014-03-28 08:27:19

Post-Market Registry to Evaluate Long-Term Safety and Performance in Routine Practice HONG KONG, March 28, 2014 /PRNewswire/ -- OrbusNeich today announced the completion of enrollment in the prospective, multicenter, all-comers REMEDEE Registry (Multicenter, Prospective, Clinical Outcomes After Deployment of the Abluminal Sirolimus Coated Bio-Engineered Stent (Combo Bio-Engineered Sirolimus Eluting Stent) Post Market Registry) to evaluate the COMBO Stent for the treatment of coronary...

2014-03-05 12:27:46

-- Rapid polymer absorption within three months coupled with drug delivery profile up to nine months provides for excellent healing -- DURHAM, N.C., March 5, 2014 /PRNewswire/ --- Micell Technologies, Inc. today announced that the long-term clinical outcomes from the DESSOLVE I and II clinical trials recently were presented at the Cardiovascular Research Technologies (CRT) Conference held in Washington, D.C., February 22 - 25. The data presentation, "MiStent SES Clinical Program:...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related